QRHC experienced a substantial revenue decline of nearly 25% coupled with worsening operating losses and a dramatically reduced capital expenditure program.
The combination of meaningful revenue contraction, deteriorating operating performance, and minimal capital investment suggests the company may be facing significant operational headwinds or market pressures. The substantial reduction in capital expenditures to just $251K indicates either severe cash preservation measures or a major pullback in growth investments, both concerning for future prospects.
QRHC's financial position deteriorated meaningfully across multiple dimensions, with revenue declining to $138.3M from $183.8M while operating losses deepened from $4.5M to $6.2M. The balance sheet contracted proportionally, with current assets falling 32% and stockholders' equity declining 25%, though total debt was reduced by 16%. Most notably, capital expenditures collapsed by nearly 95% to just $251K, signaling either acute cash constraints or a dramatic strategic shift away from growth investment.
Capex reduced 94.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Inventory drawn down 76.1% — strong sell-through or deliberate destocking; watch for supply constraints.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current assets declined 31.9% — monitor working capital adequacy and short-term liquidity.
Equity decreased 25.2% — buybacks or losses reducing book value, monitor solvency ratios.
Revenue softened 24.7% — monitor whether this is cyclical or structural.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Total assets contracted 17.1% — asset sales, write-downs, or balance sheet optimization underway.
Debt reduced 16.1% — deleveraging strengthens balance sheet and reduces financial risk.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →